Tag: editas medicine

June 22, 2020

7 Small Biotech ETFs

Want to invest in small biotech ETFs? INN profiles seven examples that life science investors may want to look into.
March 20, 2020

The Rise of CRISPR Technology

CRISPR technology is a rapidly growing component of the genetics industry. Here's what investors need to know about its future...
January 21, 2019

Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101

Editas Medicine (Nasdaq:EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology...
November 13, 2018

CRISPR Trials to Watch in 2018

CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress.
June 28, 2018

5 Top NASDAQ Genetic Stocks of Q2 2018

In the final days of Q2 2018, we've profiled the five top NASDAQ genetic stocks year-to-date. Here's a look at...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.